Checkpoint Therapeutics Q2 2022 Earnings Report
Key Takeaways
Checkpoint Therapeutics announced positive interim results from the registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma and successful completion of pre-BLA meetings.
Announced positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma in June 2022.
Successfully completed pre-BLA meetings in July 2022.
Biologics license application submission for both metastatic and locally advanced cutaneous squamous cell carcinoma on track for later this year.
Continued to advance commercial planning to enable a successful launch upon possible approval next year.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
The company is on target to submit the cosibelimab BLA in late 2022 and believes their price disruptive strategy could generate substantial market share for cosibelimab in the U.S.